Table 5.

Sensitivity Analysis Hazard Ratio Point Estimates

Covariate	Model Hazard Ratio (95% CI)
	Mild Psoriasis	Severe Psoriasis
Primary Analysis	1.06 (1.01, 1.11)	1.43 (1.10, 1.87)
At least 6 months of follow-up (to ensure capture of incident, not prevalent stroke)	1.07 (1.02, 1.13)	1.44 (1.08, 1.93)
Inclusion of patients with at least 1 GP visit per year	1.05 (1.002, 1.10)	1.40 (1.07, 1.83)
Primary Model excluding patients with history of stroke or TIA (to ensure capture of incident, not prevalent stroke)	1.08 (1.02, 1.14)	1.39 (1.02, 1.89)
Primary Model with BMI adjustment	1.03 (0.96, 1.10)	1.43 (1.02, 2.02)
Primary Model excluding patients with no BMI captured	1.03 (0.96, 1.10)	1.41 (1.004, 1.99)
Primary Model with atrial fibrillation adjustment	1.04 (0.99, 1.09)	1.46 (1.12, 1.91)
Primary model with exclusion of patients with psoriatic arthropathy	1.06 (1.01, 1.11)	1.50 (1.12, 2.00)
Primary model with exclusion of Methotrexate	NA	1.49 (1.01, 2.19)
Primary model with exclusion of oral retinoids or cyclosporine	NA	1.43 (1.07, 1.92)
Primary model with restriction of severe group to patients who have received a prescription for an oral retinoid	NA	1.45 (0.78, 2.67)
Primary model with restriction of stroke to patients who received a prescription code for anti-platelet, anti-coagulant, or thrombolytic therapy within 30 days of the stroke diagnosis.	0.99 (0.91, 1.09)	1.36 (0.80, 2.30)

Abbreviations: CI, confidence interval; TIA, transient ischemic attack; HR, hazard ratio; GP, general practioner; BMI; body mass index; NA, not applicable.